Phosphodiesterase inhibition in cognitive decline

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S561-S573

  García Barroso, Carolina ^a   Ugarte, Ana ^b   Martínez, Martín ^a   Rico, Alberto J ^b,c   Lanciego, José Luis ^b,c   Franco, Rafael ^a,d   Oyarzabal, Julen ^b   Cuadrado Tejedor, Mar ^a   García Osta, Ana ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cerebrospinal fluid; cGMP; memory enhancement; phosphodiesterase; tadalafil

Indexed keywords

CYCLIC NUCLEOTIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V; TADALAFIL; PHOSPHODIESTERASE INHIBITOR;

COGNITION; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG REPOSITIONING; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COGNITION DISORDERS; ENZYMOLOGY; METABOLISM;

ANIMALS; COGNITION DISORDERS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 84908203966     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141341     Document Type: Review

References (94)

1. Flexner JB, Flexner LB, Stellar E ( 1963) Memory in mice as affected by intracerebral puromycin. Science 141, 57-59.
2. Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR (1996) Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16, 973-982.
3. Tully T (1997) Regulation of gene expression and its role in long-term memory and synaptic plasticity. Proc Natl Acad Sci U S A 94, 4239-4241.
4. Tully T, Bourtchouladze R, Scott R, Tallman J (2003) Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2, 267-277.
5. Gonzalez GA, MontminyMR (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680.
6. Dash PK, Karl KA, Colicos MA, Prywes R, Kandel ER (1991) cAMP response element-binding protein is activated by Ca2+/calmodulin-As well as cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 88, 5061-5065.
7. LuYF, Kandel ER, HawkinsRD(1999) Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19, 10250-10261.
8. Lu YF, Hawkins RD (2002) Ryano dine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J Neurophysiol 88, 1270-1278.
9. Blokland A, Menniti FS, Prickaerts J (2012) PDE inhibition and cognition enhancement. Expert Opin Ther Pat 22, 349-354.
10. Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, Oyarzabal J, Franco R (2012) Phosphodiesterases as therapeutic targets for Alzheimer 's disease. ACS Chem Neurosci 3, 832-844.
11. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 202, 419-443.
12. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 65, 1-52.
13. Rybalkin SD, Hinds TR, Beavo JA (2013) Enzyme assays forcGMPhydrolyzing phosphodiesterases. Methods Mol Biol 1020, 51-62.
14. Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59, 367-374.
15. Garcia-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Salles J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, Garcia-Osta A (2013) Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64, 114-123.
16. Chalimoniuk M,Strosznajder JB 1998 Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum Effects of amyloid beta peptide. Mol Chem Neuropathol 35, 77-95.
17. Arancio O, Antonova I, Gambaryan S, Lohmann SM, Wood JS, Lawrence DS, Hawkins RD (2001) Presynaptic r ole of cGMP-dependent protein kinase during long-lasting potentiation. J Neurosci 21, 143-149.
18. Son H, Lu YF, Zhuo M, Arancio O, Kandel ER, Hawkins RD (1998) The specific role of cGMP in hippocampal LTP. Learn Mem 5, 231-245.
19. Kleppisch T, Feil R (2009) cGMP signalling in the mammalian brain: Role in synaptic plasticity and behaviour. Handb Exp Pharmacol 549-579.
20. Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti FS, Steinbusch HW, Prickaerts J (2012) Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms. Neurobiol Learn Mem 97, 370-379.
21. Ko IG, Shin MS, Kim BK, Kim SE, Sung YH, Kim TS, Shin MC, Cho HJ, Kim SC, Kim SH, Kim KH, Shin DH, Kim CJ (2009) Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. Pharmacol Biochem Behav 91, 629-635.
22. Gulati P, Singh N (2014) Neuroprotective effect of tadalafil, a PDE-5 inhibitor, and its modulation by L-NAME in mouse model of ischemia-reperfusion injury. J Surg Res 186, 475-483.
23. Garciá-Osta A, Cuadrado-Tejedor M, Garciá-Barroso C, Oyarzá bal J, Franco R (2012) Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci 3, 832-844.
24. Molnar P, Gaal L (1992) Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. Eur J Pharmacol 215, 17-22.
25. DeNoble VJ (1987) Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 26, 183-186.
26. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL (2009) Amelioration of intracerebroventricular streptozotocin induced co gnitive dysfunction and oxidative stress by vinpocetine-A PDE1 inhibitor. Eur J Pharmacol 620, 49-56.
27. Hindmarch I, Fuchs HH, Erzigkeit H (1991) Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6, 31-43.
28. Polli JW, Kincaid RL (1992) Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci U S A 89, 11079-11083.
29. Domek-Lopac inska K, Strosznajder JB (2008) The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216, 68-77.
30. van Donkelaar EL, Rutten K, Blokland A, Akkerman S, Steinbusch HW, Prickaerts J (2008) Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan de pletion. Eur J Pharmacol 600, 98-104.
31. Reneerkens OA, Rutten K, Bollen E, Hage T, Blokland A, Steinbusch HW, Prickaerts J (2013) Inhibition of phoshodiesterase type 2 or type 10 rever ses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 236, 16-22.
32. Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J (2013) Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology 64, 124-136.
33. Gomez L, Breitenbucher JG (2013) PDE2 inhibition: Potential for the treatment of cognitive disorders. Bioorg Med Chem Lett 23, 6522-6527.
34. Xu Y, Zhang HT, O'Donnell JM (2011) Phosphodiesterases in the central nervous system: Implications in mood and cognitive disorders. Handb Exp Pharmacol, 447-485.
35. O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J,Young IS, Lee B, Soong CV (2009) The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 37, 326-335.
36. Yanai S, Semba Y, Ito H, Endo S (2014) Cilostazol improves hippocampus-dependent long-term memory in mice. Psychopharmacology (Berl) 231, 2681-2693.
37. Hiramatsu M,Takiguchi O,Nishiyama A,Mori H 2010 Cilostazol prevents amyloid beta peptide(25-35)-induced memory impairment and oxidative stress in mice Br J Pharmacol 161,1899-1912.
38. Park SH, Kim JH, Bae SS, HongKW, Lee DS, Leem JY, Choi BT, ShinHK(2011) Protective effect of the phosphodiesterase III inhibito r cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation. Biochem Biophys Res Commun 408, 602-608.
39. Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T (2013) Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study. Geriatr Gerontol Int 13, 90-97.
40. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278, 5493-5496.
41. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC (2002) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135, 113-118.
42. Bruno O, Romussi A, Spallarossa A, Brullo C, Schenone S, Bondavalli F, Vanthuyne N, Roussel C (2009) New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isof orms. J Med Chem 52, 6546-6557.
43. Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L,WallaceTL(2008) Enhanced long-term potentiation and impaired learning in phosphodiest erase 4D-knockout (PDE4D) mice. Eur J Neurosci 28, 625-632.
44. Sierksma AS, van den Hove DL, Pfau F, Philippens M, Bruno O, Fedele E, Ricciarelli R, Steinbusch HW, Vanmierlo T, P rickaerts J (2014) Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 77, 120-130.
45. Li YF, Cheng YF, Huang Y, Co nti M, Wilson SP, O'Donnell JM, Zhang HT (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 31, 172-183.
46. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodi esterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28, 63-70.
47. Bruno O, Fedele E, Prickaerts J, Parker LA, Canepa E, Brullo C, Cavallero A, Gardella E, Balbi A, Domenicotti C, Bollen E, Gijselaers HJ, Vanmierlo T, Erb K, Limebeer CL, Argellati F, Marinari UM, Pronzato MA, Ricciarelli R (2011) GEBR-7b, a novel PDE4D selective inhibitor t hat improves memory in rodents at non-emetic doses. Br J Pharmacol 164, 2054-2063.
48. Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB (2014) GSK356278, a potent, selective, brainpenetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pha rmacol Exp Ther 350, 153-163.
49. Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, Morales-Garcia JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid MI, Loza M I, Perez-Castillo A, Mengod G, Campillo NE, Martinez A, Gil C (2012) Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem 55, 3274-3284.
50. Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, Esposito E, Martinez A, Cuzzocrea S (2011) PDE 7 inhibitors: New potent ial drugs for the therapy of spinal cord injury. PLoS One 6, e15937.
51. Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, Santos A, Perez-Castillo A (2011) Pho sphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One 6, e17240.
52. Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Perez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A, Carro E (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's dise ase. Neurobiol Aging 34, 2133-2145.
53. Morales-Garcia JA, PalomoV, Redondo M, Alonso-Gil S, Gil C, Martinez A, Perez-Castillo A (2014) Crosstalk between phosphodiesterase 7 and glycogen synt hase kinase-3: Two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci 5, 194-204.
54. Lipina TV, Palomo V, Gil C, Martinez A, Roder JC (2013) Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology 64, 205-214.
55. Tsai LC, Chan GC, Nangle SN, Shimizu-Albergine M, Jones GL, Storm DR, Beavo JA, Zweifel LS (2012) Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordin ation decay. Genes Brain Behav 11, 837-847.
56. Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, Housley W, Clark RB, Epstein PM, Brocke S (2010) PDE8 regulat es rapid Teff cell adhesion and proliferation independent of ICER. PLoS One 5, e12011.
57. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, HendrixM( 2005) Characterization of the first p otent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68, 1775-1781.
58. Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tut tle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S (2012) Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyr an-4-y l)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J Med Chem 55, 9045-9054.
59. Kroker KS, Mat his C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C (2014) PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 35, 2072-2078.
60. Clini calTrials.gov. (2009)Astudy of PF-04447943 compared to placebo in subjects with mild to moderate Alzheimer's disease, http://clinicaltrials.gov/ct2/show/NCT00930059, Accessed on 29 June 2012.
61. Giralt A, Saavedra A, Carreton O, Arumi H, Tyebji S, Alberch J, Perez-Navarro E (2013) PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. Hippocampus 2 3, 684-695.
62. Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S (2009) Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of s chizophrenia. J Med Chem 52, 5188-5196.
63. Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D Jr., Nelson CM, Spangler EL, Ingram DK (2005) Phosphodiestera se type 5 (PDE5) inhibition and cognitive enhancement. Drugs Future 30, 725-736.
64. Prickaerts J, Steinbusch HW, Smits JF, de Vente J (1997) Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinast. Eur J Pharmacol 337, 125-136.
65. Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DW, Arancio O (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci 29, 8075-8086.
66. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Perez-Roldan JM, Garcia-Barroso C, Franco R, Aguirre N, Garcia-Osta A (2011) Sildenafil restores cognitive function without affecting Ass burden in an Alzheimer's disease mouse model. Br J Pharmacol 164, 2029-2041.
67. Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, Wang Q, ZhouW, Xu Y,Wang C (2013) Phosphodiesterase-5 inhibitor sildenafil preve nts neuroinflammation, lowers beta-Amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 250, 230-237.
68. Jin F, Gong QH, Xu YS, Wang LN, Jin H, Li F, Li LS, Ma YM, Shi JS (2014) Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. Int J Neuropsychopharmacol 17, 871-881.
69. Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, Rao S, Thakkar DM, Deng SX, Landry DW, Arancio O (2013 ) Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur J Med Chem 60, 285-294.
70. Saavedra A, Giralt A, Ar umi H, Alberch J, Perez-Navarro E (2013) Regulation of hippocampalcGMPlevels as a candidate to treat cognitive deficits in Huntington's disease. PLoS One 8, e73664.
71. Baek SB, Bahn G, Moon SJ, Lee J, Kim KH, Ko IG, Kim SE, Sung YH, Kim BK, Kim TS, Kim CJ, Shin MS (2011) The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses a poptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups. Neurosci Lett 488, 26-30.
72. Zhang R,Wang Y, Zhang L, Zhang Z, TsangW, Lu M, Zhang L, Chopp M (2002 ) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33, 2675-2680.
73. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, Gollap alli L, Panda S, Li Q, Ewing JR, Chopp M (2008) Angiogenesis detected after embolic stroke in rat brain using magnetic resonance T2WI. Stroke 39, 1563-1568.
74. Zhang L, Zhang RL, W ang Y, Zhang C, Zhang ZG, Meng H, Chopp M (2005) Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke 36, 847-852.
75. Orejana L, Barros-Minones L, Jordan J, Puerta E, Aguirre N (2012) Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-Accelerated mouse model. Neurobiol Aging 33, 625 e611-620.
76. Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D Jr., Nelson CM, Spangler EL, Ingram DK (2006) Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induce d by nitric oxide synthase inhibition. Psychopharmacology (Berl) 183, 439-445.
77. Devan BD, Sierra-Mercado D Jr., Jimenez M, Bowker JL, Duffy KB, Spangler EL, Ingram DK (2004) Phospho diesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 79, 691-699.
78. Devan BD, Pistell PJ, Duffy KB, Kelley-Bell B, Spangler EL, Ingram DK (2014) Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. NeuroRehabilitation 34, 101-111.
79. Puerta E, Hervias I, Barros-Minones L, Jordan J, Ricobaraza A, Cuadrado-Tejedor M, Garcia-Osta A, Aguirre N (2010) Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38, 237-245.
80. Barros-Minones L,Martin-de-Saavedra D,Perez-Alvarez S,Orejana L,Suquia V,Goni-Allo B,Hervias I,Lopez MG,Jordan J,Aguirre N,Puerta E. Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate Biochim Biophys Acta 1832, 705-717.
81. Mattson MP, Cu lmsee C, Yu ZF (2000) Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res 301, 173-187.
82. Tamatani M, Ogawa S, Nunez G, TohyamaM(1998) Growth factor s prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ 5, 911-919.
83. Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda MV, Ar ancio O, Palmeri A (2013) Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging 35, 520-531.
84. Shim YS, Pae CU, Cho KJ, Kim SW, Kim JC, Koh JS (2014) Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: A double-blind, placebo-controlled study. Int J Imp ot Res 26, 76-80.
85. Kulkarni SK, Patil CS (2004) Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and thera peutical aspects. Methods Find Exp Clin Pharmacol 26, 789-799.
86. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI (2006) Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 61, 280-288.
87. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocam pus 22, 1040-1050.
88. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau patholog y in an Alzheimer's disease mouse model. Neuropsychopharmacology 34, 1721-1732.
89. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5161-5166.
90. Smith DL, Pozueta J, Gong B, Arancio O, ShelanskiM(2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106, 16877-16882.
91. Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ (2009) Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 4, e542 4.
92. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, Koo EH, Masliah E, Tuszynski MH (2013) Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transge nic mice. J Neurosci 33, 15596-15602.
93. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao M V, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15, 331-337.
94. van Albada SJ, Robinson PA (2007) Transformation of arbitrary distributions to the normal distribution with application to EEG test-retest reliability. J Neurosci Methods 161, 205-211.